Michael M Hubalek - Gynecology

Author Information

Michael Hubalek is a distinguished researcher affiliated with the Department of Obstetrics and Gynecology at the Medical University of Innsbruck in Innsbruck, Austria. His work primarily focuses on metastatic breast cancer (MBC), and he has contributed significantly to the understanding and treatment of this condition through various clinical trials and registry analyses.

Research Contributions

Michael Hubalek has made substantial contributions to the field of metastatic breast cancer research. His work spans several key areas, including the response patterns to chemotherapy, brain metastases from breast cancer, and the effectiveness of surgical removal of metastases in oligometastatic breast cancer. He has also investigated the treatment landscape of HER2-positive and HER2-low metastatic breast cancer, as well as the sequencing of neoadjuvant therapies. His research is often based on real-world data from the Austrian AGMT_MBC-Registry, contributing valuable insights into everyday clinical practice.

Aliases

M. Hubalek is also known by several aliases, including Michael Hubalek, Michael M Hubalek, and Michal Hubálek.

Publication and Citation Metrics

Metric	Value
Total Papers	133
Total Citations	3758
h-index	31

Publications:

Abstract P1-16-03: Response pattern to chemotherapy in metastatic breast cancer (MBC): Real-word data from the Austrian AGMT_MBC-Registry

DOI: 10.1158/1538-7445.sabcs21-p1-16-03

Year: 2022

Abstract P1-21-08: Brain metastases (BM) from breast cancer: Real-word data from the Austrian AGMT_MBC-registry

DOI: 10.1158/1538-7445.sabcs21-p1-21-08

Year: 2022

Abstract PS1-41: Does complete surgical removal of metastases in oligometastatic breast cancer improve survival? A matched-pair analysis of the AGMT_MBC-registry

DOI: 10.1158/1538-7445.SABCS20-PS1-41

Year: 2021

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)

DOI: 10.1177/17588359211042301

Year: 2021

Abstract PS12-21: First-line treatment of hormone receptor positive metastatic breast cancer (MBC) in everyday practice: Results from the Austrian AGMT_MBC-Registry

DOI: 10.1158/1538-7445.SABCS20-PS12-21

Year: 2021

283P Treatment landscape of HER2-positive metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry

DOI: 10.1016/j.annonc.2021.08.566

Year: 2021

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry

DOI: 10.1186/s13058-021-01492-x

Year: 2021

Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34

DOI: 10.1038/s41416-021-01284-2

Year: 2021

Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).

DOI: 10.1016/j.ejca.2020.03.018

Year: 2020

A Brief (Hi)Story of Just-So Stories in Evolutionary Science

DOI: 10.1177/0048393120944223

Year: 2020

Who Provides Lactation Services?

What is the Role of Hormones in Menopause?

What is the role of a gynecologist during pregnancy?

How Can Public Awareness Help?

How is Polycystic Ovary Syndrome (PCOS) Related to Menstrual Issues?

What Is the Role of Parents and Caregivers?

How Can Women Address These Issues?

What Factors Affect Sperm Quality?

Can Hormonal Imbalances Cause Cognitive Dysfunction?

How often should women practice yoga and meditation for optimal benefits?

Partnered Content Networks

Relevant Topics